Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dragonfly Therapeutics

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

Celgene building

Celgene signs $1bn immunotherapy deal with Sutro

Includes exclusive option to acquire the San Francisco-based biotech

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

Gilead Sciences

Gilead gets US approval for Sovaldi follow-up Harvoni

Company claims it could cure 90 percent of patients within eight weeks

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Gilead will file safer HIV combination before year-end

New version of Stribild is less likely to cause side effects

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links